A novel intramedullary spinal cord tumor model

functional, radiological, and histopathological characterization.

Gaurav Mavinkurve, Gustavo Pradilla, Federico G. Legnani, Betty M. Tyler, Carlos A. Bagley, Henry Brem, George Jallo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

OBJECT: Survival rates for high-grade intramedullary spinal cord tumors (IMSCTs) are approximately 30%, and optimal therapy has yet to be determined. Development of a satisfactory intramedullary tumor model is necessary for testing new therapeutic paradigms that may prolong survival. The authors report the technique, functional progression, radiological appearance, and histopathological features of a novel intramedullary model in rabbits. METHODS: Ten New Zealand white rabbits were randomized to receive an intramedullary injection of either 25 microl of VX2 carcinoma cells (500,000 cells; six rabbits) or 25 microl of medium (Dulbecco modified Eagle medium; four rabbits) into the midthoracic spinal cord. Postoperatively the rabbits were evaluated twice daily for neurological deficits. High-resolution magnetic resonance (MR) images were acquired preoperatively and weekly postoperatively until onset of paraparesis, at which point the animals were killed, and the midthoracic spines were processed for histopathological examination. The VX2-carcinoma cells grew in 100% of animals injected and resulted in a statistically significant mean onset of paraparesis of 16.8 +/- 1.7 days (p = 0.0035, log-rank test), compared with animals in the control group in which neurological deficits were absent by Day 45. Contrast-enhanced T1-weighted MR imaging best demonstrated space-occupying intramedullary lesions and histopathological findings confirmed the intramedullary location of the tumor. Animals in the control group exhibited no functional, radiographic, or pathological signs of tumor. CONCLUSIONS: Progression to paraparesis was consistent in all the VX2-injected animals, with predictable onset of paraparesis occurring approximately 17 days postinjection. Histopathological and radiological characteristics of the VX2 intramedullary tumor are comparable with those of aggressive primary human IMSCTs. Establishment of this novel animal tumor model will facilitate the testing of new therapeutic paradigms for the treatment of IMSCTs.

Original languageEnglish (US)
Pages (from-to)142-148
Number of pages7
JournalJournal of neurosurgery. Spine.
Volume3
Issue number2
StatePublished - Aug 1 2005

Fingerprint

Spinal Cord Neoplasms
Paraparesis
Rabbits
Neoplasms
Carcinoma
Control Groups
Eagles
Therapeutics
Spinal Cord
Spine
Magnetic Resonance Spectroscopy
Animal Models
Magnetic Resonance Imaging
Injections
Survival

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Neurology

Cite this

Mavinkurve, G., Pradilla, G., Legnani, F. G., Tyler, B. M., Bagley, C. A., Brem, H., & Jallo, G. (2005). A novel intramedullary spinal cord tumor model: functional, radiological, and histopathological characterization. Journal of neurosurgery. Spine., 3(2), 142-148.

A novel intramedullary spinal cord tumor model : functional, radiological, and histopathological characterization. / Mavinkurve, Gaurav; Pradilla, Gustavo; Legnani, Federico G.; Tyler, Betty M.; Bagley, Carlos A.; Brem, Henry; Jallo, George.

In: Journal of neurosurgery. Spine., Vol. 3, No. 2, 01.08.2005, p. 142-148.

Research output: Contribution to journalArticle

Mavinkurve, G, Pradilla, G, Legnani, FG, Tyler, BM, Bagley, CA, Brem, H & Jallo, G 2005, 'A novel intramedullary spinal cord tumor model: functional, radiological, and histopathological characterization.', Journal of neurosurgery. Spine., vol. 3, no. 2, pp. 142-148.
Mavinkurve, Gaurav ; Pradilla, Gustavo ; Legnani, Federico G. ; Tyler, Betty M. ; Bagley, Carlos A. ; Brem, Henry ; Jallo, George. / A novel intramedullary spinal cord tumor model : functional, radiological, and histopathological characterization. In: Journal of neurosurgery. Spine. 2005 ; Vol. 3, No. 2. pp. 142-148.
@article{0f3b6f462e374b9b948633fdfaf057a9,
title = "A novel intramedullary spinal cord tumor model: functional, radiological, and histopathological characterization.",
abstract = "OBJECT: Survival rates for high-grade intramedullary spinal cord tumors (IMSCTs) are approximately 30{\%}, and optimal therapy has yet to be determined. Development of a satisfactory intramedullary tumor model is necessary for testing new therapeutic paradigms that may prolong survival. The authors report the technique, functional progression, radiological appearance, and histopathological features of a novel intramedullary model in rabbits. METHODS: Ten New Zealand white rabbits were randomized to receive an intramedullary injection of either 25 microl of VX2 carcinoma cells (500,000 cells; six rabbits) or 25 microl of medium (Dulbecco modified Eagle medium; four rabbits) into the midthoracic spinal cord. Postoperatively the rabbits were evaluated twice daily for neurological deficits. High-resolution magnetic resonance (MR) images were acquired preoperatively and weekly postoperatively until onset of paraparesis, at which point the animals were killed, and the midthoracic spines were processed for histopathological examination. The VX2-carcinoma cells grew in 100{\%} of animals injected and resulted in a statistically significant mean onset of paraparesis of 16.8 +/- 1.7 days (p = 0.0035, log-rank test), compared with animals in the control group in which neurological deficits were absent by Day 45. Contrast-enhanced T1-weighted MR imaging best demonstrated space-occupying intramedullary lesions and histopathological findings confirmed the intramedullary location of the tumor. Animals in the control group exhibited no functional, radiographic, or pathological signs of tumor. CONCLUSIONS: Progression to paraparesis was consistent in all the VX2-injected animals, with predictable onset of paraparesis occurring approximately 17 days postinjection. Histopathological and radiological characteristics of the VX2 intramedullary tumor are comparable with those of aggressive primary human IMSCTs. Establishment of this novel animal tumor model will facilitate the testing of new therapeutic paradigms for the treatment of IMSCTs.",
author = "Gaurav Mavinkurve and Gustavo Pradilla and Legnani, {Federico G.} and Tyler, {Betty M.} and Bagley, {Carlos A.} and Henry Brem and George Jallo",
year = "2005",
month = "8",
day = "1",
language = "English (US)",
volume = "3",
pages = "142--148",
journal = "Journal of Neurosurgery: Spine",
issn = "1547-5654",
publisher = "American Association of Neurological Surgeons",
number = "2",

}

TY - JOUR

T1 - A novel intramedullary spinal cord tumor model

T2 - functional, radiological, and histopathological characterization.

AU - Mavinkurve, Gaurav

AU - Pradilla, Gustavo

AU - Legnani, Federico G.

AU - Tyler, Betty M.

AU - Bagley, Carlos A.

AU - Brem, Henry

AU - Jallo, George

PY - 2005/8/1

Y1 - 2005/8/1

N2 - OBJECT: Survival rates for high-grade intramedullary spinal cord tumors (IMSCTs) are approximately 30%, and optimal therapy has yet to be determined. Development of a satisfactory intramedullary tumor model is necessary for testing new therapeutic paradigms that may prolong survival. The authors report the technique, functional progression, radiological appearance, and histopathological features of a novel intramedullary model in rabbits. METHODS: Ten New Zealand white rabbits were randomized to receive an intramedullary injection of either 25 microl of VX2 carcinoma cells (500,000 cells; six rabbits) or 25 microl of medium (Dulbecco modified Eagle medium; four rabbits) into the midthoracic spinal cord. Postoperatively the rabbits were evaluated twice daily for neurological deficits. High-resolution magnetic resonance (MR) images were acquired preoperatively and weekly postoperatively until onset of paraparesis, at which point the animals were killed, and the midthoracic spines were processed for histopathological examination. The VX2-carcinoma cells grew in 100% of animals injected and resulted in a statistically significant mean onset of paraparesis of 16.8 +/- 1.7 days (p = 0.0035, log-rank test), compared with animals in the control group in which neurological deficits were absent by Day 45. Contrast-enhanced T1-weighted MR imaging best demonstrated space-occupying intramedullary lesions and histopathological findings confirmed the intramedullary location of the tumor. Animals in the control group exhibited no functional, radiographic, or pathological signs of tumor. CONCLUSIONS: Progression to paraparesis was consistent in all the VX2-injected animals, with predictable onset of paraparesis occurring approximately 17 days postinjection. Histopathological and radiological characteristics of the VX2 intramedullary tumor are comparable with those of aggressive primary human IMSCTs. Establishment of this novel animal tumor model will facilitate the testing of new therapeutic paradigms for the treatment of IMSCTs.

AB - OBJECT: Survival rates for high-grade intramedullary spinal cord tumors (IMSCTs) are approximately 30%, and optimal therapy has yet to be determined. Development of a satisfactory intramedullary tumor model is necessary for testing new therapeutic paradigms that may prolong survival. The authors report the technique, functional progression, radiological appearance, and histopathological features of a novel intramedullary model in rabbits. METHODS: Ten New Zealand white rabbits were randomized to receive an intramedullary injection of either 25 microl of VX2 carcinoma cells (500,000 cells; six rabbits) or 25 microl of medium (Dulbecco modified Eagle medium; four rabbits) into the midthoracic spinal cord. Postoperatively the rabbits were evaluated twice daily for neurological deficits. High-resolution magnetic resonance (MR) images were acquired preoperatively and weekly postoperatively until onset of paraparesis, at which point the animals were killed, and the midthoracic spines were processed for histopathological examination. The VX2-carcinoma cells grew in 100% of animals injected and resulted in a statistically significant mean onset of paraparesis of 16.8 +/- 1.7 days (p = 0.0035, log-rank test), compared with animals in the control group in which neurological deficits were absent by Day 45. Contrast-enhanced T1-weighted MR imaging best demonstrated space-occupying intramedullary lesions and histopathological findings confirmed the intramedullary location of the tumor. Animals in the control group exhibited no functional, radiographic, or pathological signs of tumor. CONCLUSIONS: Progression to paraparesis was consistent in all the VX2-injected animals, with predictable onset of paraparesis occurring approximately 17 days postinjection. Histopathological and radiological characteristics of the VX2 intramedullary tumor are comparable with those of aggressive primary human IMSCTs. Establishment of this novel animal tumor model will facilitate the testing of new therapeutic paradigms for the treatment of IMSCTs.

UR - http://www.scopus.com/inward/record.url?scp=33644666353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644666353&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 142

EP - 148

JO - Journal of Neurosurgery: Spine

JF - Journal of Neurosurgery: Spine

SN - 1547-5654

IS - 2

ER -